Mallinckrodt Guts IP Suit Amid Oxide Rival's New Drug App

By Kelly Lienhard · February 13, 2024, 3:08 PM EST

A Delaware federal judge has dismissed 10 of the originally asserted 14 patents in pharmaceutical company Mallinckrodt's claims against a French industrial gas company over a generic version of its pediatric...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Mallinckrodt Pharmaceuticals Ireland Limited et al v. Airgas Therapeutics LLC et al

Case Number

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

December 30, 2022

Recent Articles By Kelly

January 30, 2024
Allergan Asks 9th Circ. To Ignore Atty's Claims Of Fraud
January 29, 2024
McCarter & English Urges Against Updating Malpractice Suit
January 05, 2024
Sarepta Avoids IP Claims As Judge Finds UPenn Patent Invalid
January 03, 2024
Judge Pauses Apple Patent Suit Ahead Of PTAB Decision
December 11, 2023
Chamber Finds Drug Price Measures Will Stifle Research
December 08, 2023
New Drug Patent Proposal Sparks Worry Over Gov't Overstep
December 07, 2023
Biden Admin Looks To Take Over Expensive Drug Patents
December 01, 2023
Med Tech Co. Sues AI Maker Over Use Of 'Judi' Mark
November 17, 2023
Calif. Prosthetics Co. Says Sales Manager Stole Trade Secrets
November 09, 2023
Regeneron Hits Rival With Patent Suit Over Eye Med Generic